Intermediate risk prostate cancer research hub
4 indexed studies · 2 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer: the ENHANCE prospective feasibility trial
This study looks at combining a heat-based ultrasound treatment (HIFU) with a short course of hormone therapy for men with intermediate-risk prostate cancer. Researchers want to see if treating just the affected part of the prostate destroys the cancer while protecting everyday urinary and sexual function over one year.
France - recruitingNA
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
This study looks at treating early prostate cancer with just 3 daily radiotherapy sessions instead of 5. It uses a special tracking system, like a GPS, to make sure the treatment is super accurate, aiming for fewer side effects and better comfort for patients. It's for men with early-stage prostate cancer.
United Kingdom - active not recruiting
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
This study looks at how well combined special scans (PSMA-PET/CT and MRI) can show prostate cancer inside the prostate, how far it's spread, and its aggressiveness in men with medium to high-risk prostate cancer, before removal surgery.
Austria · Belgium · Germany - authorisedTherapeutic exploratory (Phase II)
Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO)
This study looks at a new way to treat prostate cancer. It combines a special, shorter course of radiation therapy with a new oral medicine called relugolix. The aim is to see how well this treatment can lower a specific marker (PSA) in the blood for men with intermediate-risk prostate cancer.
Italy